Montréal, Canada – July 07, 2016: The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) is pleased to announce the appointment of the following Directors to its Board, Mr. Fréderic Alberro – Director, Quebec, Innovative Medicines Canada (previously Rx&D), Mr. Jacques Bernier – President and Managing Partner at Teralys Capital, Mr. Andrew Casey – President and Chief Executive Officer at BIOTECanada and Mr. Pierre Fontaine – Executive Assistant Director of Research – CIUSSS Montreal-East end.
These four new directors bring a range of expertise complementary to the one already in place within the Board. They will enrich our business discussions on issues relating to biotechnology, the pharmaceutical industry and venture capital, with key government matters in mind.
Ms. Johane Boucher-Champagne, Chair of IRICoR’s Board of Directors, comments “I am happy to be able to rely on such a roaster of experienced individuals at the Board. The arrival of these new directors emphasizes IRICoR’s brand positioning as a valorisation cluster for state-of-the-art academic research geared towards commercialization of highly innovative drugs. Our Board members are all experts in their respective fields and represent a strategic asset for the organization. Welcome to our new directors! “.
For more information on IRICoR and all Board members of the organization, please visit our website at the following address: www.iricor.ca